Zhang Shiyu, Zhang Lingge, Wu Hao, Li Lu
The First Affiliated Hospital of Xi'an Medical University, No. 48, Fenghao West Road, Lianhu District, Xi'an, 710077, Shaanxi, China.
Int Urol Nephrol. 2025 May 27. doi: 10.1007/s11255-025-04563-6.
Currently, the proportion of haemodialysis patients with combined sarcopenia is as high as 13.7%, and the prevalence of sarcopenia in patients over 60 years of age is 33.3%. At present, the pathogenesis of combined sarcopenia in dialysis patients and the intervention strategies are still unclear, and the aim of this paper is to explore the pathogenesis of sarcopenia in haemodialysis patients and the clinical management strategies to improve the patients' prognosis and quality of life.
The relationship between sarcopenia and microinflammation and protein metabolic imbalance was analysed and the effects of nutritional supplementation, exercise and pharmacological treatment were assessed.
The management of sarcopenia, which is critical for improving quality of life in haemodialysis patients, is associated with multiple factors, including microinflammation, reduced protein synthesis, and hormonal dysregulation. This article proposes an integrated management strategy of diet, exercise and pharmacotherapy and explores new therapeutic targets such as methylglyoxal to improve patient prognosis.
目前，合并肌肉减少症的血液透析患者比例高达13.7%，60岁以上患者的肌肉减少症患病率为33.3%。目前，透析患者合并肌肉减少症的发病机制及干预策略仍不明确，本文旨在探讨血液透析患者肌肉减少症的发病机制及改善患者预后和生活质量的临床管理策略。
分析肌肉减少症与微炎症和蛋白质代谢失衡之间的关系，并评估营养补充、运动和药物治疗的效果。
肌肉减少症的管理对改善血液透析患者的生活质量至关重要，其与多种因素相关，包括微炎症、蛋白质合成减少和激素失调。本文提出饮食、运动和药物治疗的综合管理策略，并探索如甲基乙二醛等新的治疗靶点以改善患者预后。
